other glp 1 receptor agonists GLP-1 in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways Comparing Ozempic, Wegovy and Other

It was found that for subjects treated with its highest dose, the cardiovascular risk of tirzepatide treatment was a low risk of 0.5, with only 11 MACE being recorded as compared to 62 MACE with insulin glargine [26]

Several agents have shown cardiovascular outcome benefits in select populations, which guides therapy selection for people with existing atherosclerotic cardiovascular disease

Financial support for this research, including the article processing charge (APC), was obtained and received by J.L

Obesity in patients with type 1 diabetes: links, risks and management challenges

In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]

Evidence supports an indirect relationship mediated by weight reduction, improved insulin sensitivity, and normalization of hormonal and inflammatory pathways